Quest Diagnostics Struggles Continue in Q3

Quest Diagnostics followed up its earlier release of disappointing preliminary third-quarter results with more details behind the under performance and pulled back its outlook for the full year. The addition of this information has not materially changed our assumptions and we are holding steady on our $65 fair value estimate. Despite the new management team’s well-publicized plans to improve Quest’s operations and enhance efficiencies, we … Continue reading Quest Diagnostics Struggles Continue in Q3